Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome

Journal of Medicinal Chemistry

Volumn 53, Issue 3, 2010, Pages 1076-1085

  Mizuno, Cassia S ^a   Chittiboyina, Amar G ^a   Shah, Falgun H ^a   Patny, Akshay ^a   Kurtz, Theodore W ^c   Pershadsingh, Harrihar A ^d   Speth, Robert C ^b,e   Karamyan, Vardan T ^b,f   Carvalho, Paulo B ^a   Avery, Mitchell A ^a,b,e,g  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MISSISSIPPI   (United States)

^f TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIBENZIMOL; ROSIGLITAZONE; TELMISARTAN;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METABOLIC SYNDROME X; MOLECULAR INTERACTION; STEREOCHEMISTRY; TRANSACTIVATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; CELL MEMBRANE; CELLS, CULTURED; DRUG DESIGN; LIVER; METABOLIC SYNDROME X; MODELS, CHEMICAL; PPAR GAMMA; RADIOLIGAND ASSAY; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; TRANSCRIPTIONAL ACTIVATION;

EID: 77249139739     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901272d     Document Type: Article

References (32)

1. Grundy, S. M.; Brewer, H. B., Jr.; Cleeman, J. I.; Smith, S. C., Jr.; Lenfant, C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109, 433-438.
2. Ford Earl, S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28, 1769-1778.
3. Cameron, A. J.; Shaw, J. E.; Zimmet, P. Z. The metabolic syndrome: prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 2004, 33, 351-375, Table of Contents.
4. Zimmet, P.; Alberti, K. G. M. M.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature (London) 2001, 414, 782-787.
5. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today 2004, 9, 641-651.
6. Edwards, I. R.; Aronson, J. K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356, 1255-1259.
7. Morphy, R.; Rankovic, Z. The Physicochemical Challenges of Designing Multiple Ligands. J. Med. Chem. 2006, 49, 4961-4970.
8. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. J. Med. Chem. 2005, 48, 6523-6543.
9. Rubenstrunk, A.; Hanf, R.; Hum, D. W.; Fruchart, J.-C.; Staels, B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2007, 1771, 1065-1081.
10. Inguimbert, N.; Poras, H.; Teffo, F.; Beslot, F.; Selkti, M.; Tomas, A.; Scalbert, E.; Bennejean, C.; Renard, P.; Fournie-Zaluski, M.-C.; Roques, B.-P.N-2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): in vitro and in vivo activities. Bioorg. Med. Chem. Lett. 2002, 12, 2001-2005.
11. Flynn, G. A.; Beight, D. W.; Mehdi, S.; Koehl, J. R.; Giroux, E. L.; French, J. F.; Hake, P. W.; Dage, R. C. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 1993, 36, 2420-2423.
12. Robl, J. A.; Sun, C.-Q.; Stevenson, J.; Ryono, D. E.; Simpkins, L. M.; Cimarusti, M. P.; Dejneka, T.; Slusarchyk, W. A.; Chao, S.; Stratton, L.; Misra, R. N.; Bednarz, M. S.; Asaad, M. M.; Cheung, H. S.; Abboa-Offei, B. E.; Smith, P. L.; Mathers, P. D.; Fox, M.; Schaeffer, T. R.; Seymour, A. A.; Trippodo, N. C. Dual Metalloprotease Inhibitors: Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase. J. Med. Chem. 1997, 40, 1570-1577.
13. Xu, Y.; Rito, C. J.; Etgen, G. J.; Ardecky,R. J.; Bean, J. S.; Bensch, W. R.; Bosley, J. R.; Broderick, C. L.; Brooks, D. A.; Dominianni, S. J.; Hahn, P. J.; Liu, S.; Mais, D. E.; Montrose-Rafizadeh, C.; Ogilvie, K. M.; Oldham, B. A.; Peters, M.; Rungta, D. K.; Shuker, A. J.; Stephenson, G. A.; Tripp, A. E.; Wilson, S. B.; Winneroski, L. L.; Zink, R.; Kauffman, R. F.; McCarthy, J. R. Design and Synthesis of α-Aryloxy-α-methylhydrocinnamic Acids: A Novel Class of Dual Peroxisome Proliferator-Activated Receptor α/γ Agonists. J. Med. Chem. 2004, 47, 2422-2425.
14. Henke, B. R. Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes. J. Med. Chem. 2004, 47, 4118-4127.
15. Benson, S. C.; Pershadsingh, H. A.; Ho, C. I.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi, N.; Wang, J.; Avery, M. A.; Kurtz, T. W. Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ-Modulating Activity. Hypertension 2004, 43, 993-1002.
16. Chittiboyina, A. G.; Mizuno, C. S.; Desai, P. V.; Patny, A.; Kurtz, T. W.; Pershadsingh, H. A.; Speth, R. C.; Karamyan, V.; Avery, M. A. Design, synthesis, and docking studies of novel telmisartan-glitazone hybrid analogs for the treatment of metabolic syndrome. Med. Chem. Res. 2009, 18, 589-610.
17. Mizuno, C. S.; Chittiboyina, A. G.; Patny, A.; Kurtz, T. W.; Pershadsingh, H. A.; Speth, R. C.; Karamyan, V. T.; Avery,M. A. Design, synthesis, and docking studies of telmisartan analogs for the treatment of metabolic syndrome. Med. Chem. Res. 2009, 611-628.
18. Chakravarty, P. K.; Patchett, A. A.; Camara, V. J.; Walsh, T. F.; Greenlee, W. J. Preparation and formulation of benzimidazoles as angiotensin II antagonists. Patent 90-305179 400835, 19900514, 1990.
19. Larhed, M.; Hallberg, A. Microwave-Promoted Palladium-Catalyzed Coupling Reactions. J. Org. Chem. 1996, 61, 9582-9584.
20. Steggles, D. J.; Verge, J. P. Pharmaceutical ethanone compounds. Patent 84-304759 132124, 19840712, 1985.
21. Santhosh, K. C.; Paul, G. C.; De Clercq, E.; Pannecouque, C.; Witvrouw, M.; Loftus, T. L.; Turpin, J. A.; Buckheit, R. W., Jr.; Cushman, M. Correlation of anti-HIV activity with anion spacing in a series of cosalane analogs with extended polycarboxylate pharmacophores. J. Med. Chem. 2001, 44, 703-714.
22. Brooks, D. A.; Godfrey, A. G.; Jones, S. B.; McCarthy, J. R.; Rito, C. J.; Winneroski, L. L., Jr.; Xu, Y. Preparation of oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists. Patent 2001-US22616 2002016331, 20010823, 2002.
23. Patny, A.; Desai, P. V.; Avery, M. A. Ligand-supported homology modeling of the human angiotensin II type 1 (AT1) receptor: insights into the molecular determinants of telmisartan binding. Proteins: Struct., Funct., Bioinf. 2006, 65, 824-842.
24. Balmforth, A. J.; Lee, A. J.; Warburton, P.; Donnelly, D.; Ball, S. G. The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J. Biol. Chem. 1997, 272, 4245-4251.
25. Hoe, K.-L.; Saavedra, J.M. Site-directed mutagenesis of the gerbil and human angiotensin II AT1 receptors identifies amino acid residues attributable to the binding affinity for the nonpeptidic antagonist losartan. Mol. Pharmacol. 2002, 61, 1404-1415.
26. Ries, U. J.; Mihm, G.; Narr, B.; Hasselbach, K. M.; Wittneben, H.; Entzeroth, M.; van Meel, J. C.; Wienen, W.; Hauel, N. H. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J. Med. Chem. 1993, 36, 4040-51.
27. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-gamma. Nature 1998, 395, 137-143.
28. Lemberger, T.; Desvergne, B.; Wahli, W. Peroxisome proliferatoractivated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu. Rev. Cell Dev. Biol. 1996, 12, 335-363.
29. Goebel, M.; Clemenz, M.; Staels, B.; Unger, T.; Kintscher, U.; Gust, R. Characterization of new PPARgamma agonists: analysis of telmisartan's structural components. ChemMedChem 2009, 4, 445-456.
30. Tagami, T.; Yamamoto, H.; Moriyama, K.; Sawai, K.; Usui, T.; Shimatsu, A.; Naruse, M. A selective peroxisome proliferatoractivated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology 2009, 150, 862-870.
31. Speth, R. C. Sarcosine1, glycine8 angiotensin II is an AT1 angiotensin II receptor subtype selective antagonist. Regul. Pept. 2003, 115, 203-209.
32. Speth, R. C.; Harding, J. W. Radio labeling of angiotensin peptides. Methods Mol. Med. 2001, 51, 275-295.